Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience
暂无分享,去创建一个
E. Shpall | R. Orlowski | Y. Nieto | Q. Bashir | M. Qazilbash | R. Champlin | Sheeba K. Thomas | D. Weber | G. Tang | D. Milton | P. Kebriaei | K. Patel | A. Masood | J. Ramdial | O. Pasvolsky | S. Srour | N. Saini | Hans C. Lee | M. Gaballa | P. Lin | Sophiya S. Sami | Mark R. Tanner | Mark R Tanner
[1] N. Munshi,et al. Location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of high-risk NDMM patients. , 2022, Blood.
[2] E. Shpall,et al. Lenalidomide-Based Maintenance After Autologous Hematopoietic Stem Cell Transplant for Patients with High-Risk Multiple Myeloma. , 2022, Transplantation and cellular therapy.
[3] A. Krishnan,et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. , 2022, The New England journal of medicine.
[4] K. Rezvani,et al. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance , 2021, Leukemia & lymphoma.
[5] S. Jagannath,et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study , 2021, The Lancet.
[6] H. Goldschmidt,et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. , 2021, The New England journal of medicine.
[7] Shuku Sato,et al. Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents , 2020, International Journal of Hematology.
[8] C. Hofmeister,et al. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Krishnan,et al. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] H. Goldschmidt,et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.
[11] H. Goldschmidt,et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. , 2016, Blood.
[12] A. El-Ghammaz,et al. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis , 2016, Annals of Hematology.
[13] H. Goldschmidt,et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Miguel,et al. Defining and treating high-risk multiple myeloma , 2015, Leukemia.
[15] S. Lonial,et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients , 2014, Leukemia.
[16] B. Pégourié,et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.
[17] I. Bruns,et al. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] P. Moreau,et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. Moreau,et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] B. Grosbois,et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials , 2007, Leukemia.
[21] J. Keats,et al. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma , 2006, Leukemia & lymphoma.
[22] D. Reece,et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant , 2004, British journal of haematology.
[23] Tony Reiman,et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.
[24] R. Bataille,et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. , 2002, Blood.